KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Free Cash Flow: 2009-2025

Historic Free Cash Flow for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Sep 2025 value amounting to $340.2 million.

  • Biomarin Pharmaceutical's Free Cash Flow rose 67.59% to $340.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $832.1 million, marking a year-over-year increase of 160.13%. This contributed to the annual value of $487.4 million for FY2024, which is 679.02% up from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Free Cash Flow stood at $340.2 million for Q3 2025, which was up 102.32% from $168.2 million recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Free Cash Flow ranged from a high of $340.2 million in Q3 2025 and a low of -$98.4 million during Q1 2023.
  • Moreover, its 3-year median value for Free Cash Flow was $113.9 million (2023), whereas its average is $110.5 million.
  • As far as peak fluctuations go, Biomarin Pharmaceutical's Free Cash Flow tumbled by 184.37% in 2022, and later surged by 11,682.78% in 2024.
  • Biomarin Pharmaceutical's Free Cash Flow (Quarterly) stood at -$17.6 million in 2021, then plummeted by 64.61% to -$28.9 million in 2022, then surged by 95.04% to -$1.4 million in 2023, then soared by 11,682.78% to $166.1 million in 2024, then spiked by 67.59% to $340.2 million in 2025.
  • Its last three reported values are $340.2 million in Q3 2025, $168.2 million for Q2 2025, and $157.6 million during Q1 2025.